Children & Adolescents
Children & Adolescents
AIDS 2012: New Antiretrovirals Formulations for Children Are Promising, More Still Needed
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 August 2012 00:00
- Written by Carole Leach-Lemens
Promising new formulations of antiretroviral agents including tenofovir and fosamprevanir for treating the often neglected needs of infants and children with HIV were presented in an oral abstract session at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV positive adolescents.
AIDS 2012: Adolescent Antiretroviral Options Expanding
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 August 2012 00:00
- Written by Carole Leach-Lemens
A range of new antiretroviral drugs are in development for adolescents with HIV, a population which may have extensive experience with antiretroviral therapy and resistance to some of the most commonly used drugs, researchers reported at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC. Related presentations covered new treatments for HIV-infected infants and children. 
FDA Approves Etravirine (Intelence) for Children with HIV
- Details
- Category: HIV Treatment
- Published on Friday, 30 March 2012 00:00
- Written by Press Release
The U.S. Food and Drug Administration (FDA) this week expanded the indication for Janssen's NNRTI etravirine (brand name Intelence) for use by treatment-experienced children (age 6-18 years) with drug-resistant HIV. The FDA also approved a new 25 mg scored tablet for easier use by pediatric patients, expected to be available in May.
FDA Approves New Fosamprenavir Dose Regimen, Nevirapine Tablets for HIV+ Children
- Details
- Category: HIV Treatment
- Published on Wednesday, 02 May 2012 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has approved new dosing recommendations for use of fosamprenavir (Lexiva) oral suspension for children with HIV. The agency also approved a generic nevirapine tablet for use by HIV positive children in PEPFAR countries.
CROI 2012: Infants with HIV Who Receive Early ART Can Safely Stop Treatment
- Details
- Category: HIV Disease Progression
- Published on Thursday, 22 March 2012 00:00
- Written by Press Release
HIV-infected infants who start antiretroviral therapy (ART) immediately after birth can interrupt treatment after 1-2 years and still do better than babies who delayed ART initiation until they developed symptoms, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.
More Articles...
- FDA Approves New Tenofovir (Viread) Formulation and Dosing Regimen for HIV+ Children
- Pediatric Dose Recommendations for Darunavir (Prezista) and Raltegravir (Isentress)
- Teens Should Receive Routine HIV Testing, Says American Academy of Pediatrics
- DHHS Issues Updated Pediatric Antiretroviral Treatment Guidelines
Web Design and Development by